NEW YORK – Castle Biosciences announced Thursday its DecisionDx-Melanoma test has received expanded coverage from Medicare Administrative Contractor Palmetto for patients with cutaneous melanoma.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.